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Introduction
Since its introduction in the 1980s, the frequency of
outpatient parenteral antibiotic therapy (OPAT) in
the USA has been increasing (1,2). Advantages of
OPAT include reduced hospital stays and patient
convenience. Guidelines for OPAT incorporate crite-
ria for proper patient and antimicrobial selection
(3,4). Antimicrobials with long half-lives are exten-
sively prescribed; those that can be administered
once a day reduce disruption of the patients’ daily
activities and limit potential complications (5).
Daptomycin (Cubicin
 ; Lexington, MA, USA), a
novel lipopeptide antibiotic with rapid in vitro bac-
tericidal activity against gram-positive pathogens,
has been approved for treatment of the following
conditions: (i) complicated skin and skin structure
infections (cSSSI) because of susceptible strains of
certain gram-positive microorganisms including
methicillin-resistant Staphylococcus aureus (MRSA),
at a dose of 4 mg⁄kg per day intravenously and
(ii) bacteremia and right-sided endocarditis because
of MRSA and methicillin-sensitive S. aureus,a ta
dose of 6 mg⁄kg per day intravenously (6,7). Clini-
cal studies have demonstrated the efﬁcacy of dapto-
mycin in these indications, but little is known
about the postapproval experience with this drug
administered as OPAT. Data from patients treated
in 2005 in the Cubicin Outcomes Registry and
Experience (CORE 2005), a retrospective observa-
tional chart review of patients who had received
daptomycin, were used in this analysis. Characteris-
tics and clinical outcomes of patients enrolled in
CORE 2005 who received OPAT or inpatient par-
enteral antibiotic therapy (IPAT) were compared
and contrasted.
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SUMMARY
Aim: To compare and contrast the characteristics and clinical outcomes of patients
who have received daptomycin as outpatients and inpatients. Methods: The Cubi-
cin Outcomes Registry and Experience (CORE) is a retrospective chart review of
patients who have received daptomycin in participating institutions. Patients trea-
ted in 2005 were included in this analysis. Demographic characteristics and clinical
outcomes (success = cured + improved) were compared among patients who
received outpatient parenteral antibiotic therapy (OPAT) and patients who had
received inpatient parenteral antibiotic therapy (IPAT). Results: Of 1172 patients
reported by 52 CORE 2005 participating institutions⁄investigators, 949 (81.0%)
patients were evaluable: 539 (56.8%) received OPAT (OPAT patients), and 410
(43.2%) received only IPAT (IPAT patients). Of the 539 OPAT patients, 273
(50.6%) also received some IPAT, usually preceding OPAT therapy. Successful out-
comes [no. of successes⁄(no. of successes + no. of failures)] for OPAT patients vs.
IPAT patients were 94.6% and 86.3% respectively (chi-square test, p < 0.001).
OPAT patients were younger, had fewer underlying diseases, were clinically stable,
and had fewer adverse events than IPAT patients. Conclusions: Outpatient paren-
teral antibiotic therapy use was common (539⁄949 or 56.8%) among patients in
CORE 2005. Clinical outcomes among OPAT patients appeared at least as good as
or better than IPAT patients. Better outcomes among OPAT patients were most
likely because of patient selection for OPAT. Additional studies should focus on
clinical characteristics of patients who would be ideal candidates for daptomycin
OPAT.
What’s known
Outpatient parenteral antibiotic therapy (OPAT) is
becoming increasingly important for treating
patients requiring intravenous antibiotic therapy.
Daptomycin, a novel lipopeptide intravenous
antibiotic with rapid bactericidal activity against
gram-positive pathogens, has many features,
including once-daily dosing, that make it attractive
for OPAT therapy. Little information is available
about the outcomes of patients who have received
daptomycin OPAT.
What’s new
Among a cohort of patients in the 2005 Cubicin
Outcomes Registry and Experience (CORE) who
received daptomycin for gram-positive infections,
outcomes among patients receiving OPAT were as
good as or better than those receiving only
inpatient parenteral antibiotic therapy (IPAT).
Patient selection for OPAT was probably a major
explanation of this ﬁnding. The frequency of
antibiotic discontinuations for adverse events during
OPAT therapy compared favourably to literature
reports of other antibiotics used in OPAT.
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General description of CORE and retrospective
chart review
A standardised case report form and protocol were
used to collect demographic and clinical informa-
tion on patients who had been treated with dapto-
mycin in 52 separate institutions in the USA
during the time period of January–December 2005.
A mix of acute care inpatient facilities, outpatient
infusion centres, and home infusion centres were
selected based on daptomycin use and willingness
to participate in the registry. After institutional
review board approval, demographic and clinical
information was collected from patient medical
records by trained study investigators in each site.
Demographic information included patient gender,
age group, weight, setting in which the patient was
located in the 48 h prior to initiating daptomycin
therapy, and patient location at the time of dapto-
mycin administration (i.e. inpatient or outpatient
setting). Clinical information included history of
underlying diseases, infection types for which dap-
tomycin was prescribed, dose and frequency of
daptomycin administration, prior antibiotic therapy,
clinical response to treatment and adverse events.
A maximum of 30 records were reviewed from
each institution. In cases where institutions had
more than 30 patients treated with daptomycin,
investigators were instructed to randomly select 30
patient records for review. Eligible patients received
at least one dose of daptomycin and were not part
of a controlled clinical trial.
Clinical outcomes
Clinical outcomes were deﬁned as:
• Cure: Clinical signs and symptoms resolved and⁄or
no additional antibiotic therapy was necessary, or the
infection cleared with a negative culture reported at
the end of daptomycin therapy.
• Improved: Partial resolution of clinical signs and
symptoms and⁄or additional antibiotic therapy was
necessary at the end of daptomycin therapy.
• Failure: Inadequate response to daptomycin ther-
apy; or, resistant, worsening or new⁄recurrent signs
and symptoms; or, there was a need for a change in
antibiotic therapy; or, a positive culture was reported
at the end of therapy.
• Non-evaluable: Unable to determine response at
the end of daptomycin therapy because the record(s)
did not contain adequate information.
Non-evaluable patients were excluded from the
analysis. Infections in patients having more than
one primary infection for which daptomycin was
prescribed were arranged in a hierarchical order
according to clinical severity, speciﬁcally, endocar-
ditis > bacteremia > osteomyelitis > other invasive
infections > cSSSI > uncomplicated skin and skin
structure infections (ucSSSI).
Statistical analysis
For purposes of analysis, patients classiﬁed as ‘cure’
or ‘improved’ were combined (i.e. success). The per
cent success was calculated as follows: no. of suc-
cesses⁄(no. of successes + no. of failures). Categorical
data were analysed using Fisher’s exact test or
chi-square test as appropriate. If overall categorical
statistical tests were signiﬁcant (p < 0.05) then indi-
vidual (subset) comparisons were performed. No
adjustments were made for multiple comparisons.
Continuous variables were tested by the t-test or
median test as appropriate.
Results
Overview
Of 1172 patients reported by 52 CORE 2005 partici-
pating institutions⁄investigators, 949 (81.0%)
patients were evaluable. OPAT institutions⁄investiga-
tors (e.g. infusion centres) accounted for 19 (36.5%)
of the 52 participating institutions⁄investigators, and
for 539 (56.8%) of the 949 patients in this analysis.
The 223 unevaluable patients were comprised of
210 patients initially classiﬁed by institutional inves-
tigators as unevaluable or ‘other’, and an additional
13 patients (two cured, 10 improved and one failure)
in whom either OPAT and⁄or IPAT daptomycin
dosing was missing.
Characteristics of evaluable and unevaluable
patients (data not shown)
A comparison of evaluable and unevaluable patients
revealed that a signiﬁcantly higher proportion of
unevaluable patients received IPAT, had bacteremia,
and had more underlying diseases. Conversely, a
higher proportion of evaluable patients had no
underlying diseases, had cSSSI or had ucSSSI.
OPAT and IPAT patient groupings
Among the evaluable patients, 266 (28.0%) received
OPAT only, 410 (43.2%) received IPAT only, and
273 (28.8%) received IPAT plus OPAT. The majority
of patients in the latter category included patients
who continued their daptomycin intravenous therapy
as outpatients. Overall, outcome (i.e. per cent suc-
cess) for the patients who received only OPAT
(93.6%) when compared with patients who received
IPAT plus OPAT (95.6%) was not statistically signiﬁ-
cantly different (p = 0.34, Fisher’s exact test, two
tailed). Therefore, unless indicated otherwise, for the
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any OPAT were combined and are referred to as
OPAT patients (n = 539). Patients who received only
IPAT are referred to as IPAT patients (n = 410).
Demographics and other characteristics
of evaluable patients
In contrast to IPAT patients, OPAT patients
tended to be female, younger and community resi-
dents in the 48 h prior to initiation of daptomycin
therapy; to have only one primary infection for
which daptomycin was prescribed; and to have
fewer underlying diseases (Table 1). The inpatient
healthcare setting in which daptomycin was ﬁrst
administered differed among OPAT and IPAT
patients: 31 (5.8%) of 539 OPAT patients versus
93 (22.7%) of 410 IPAT patients were located in
medical or surgical intensive care or coronary care
units at the time daptomycin was ﬁrst adminis-
tered (p < 0.0001, chi-square test).
Type of infection, location, pathogens and
clinical outcomes of daptomycin treatment
Proportionately more IPAT patients had bacteremia,
and more OPAT patients had osteomyelitis and
ucSSSI (Table 2). Staphylococci accounted for 595
(76.1%) of 782 infections for which a pathogen was
identiﬁed; S. aureus accounted for over half of the
staphylococcal infections. Enterococci were the sec-
ond most common group of pathogens, accounting
for 124 (15.9%) of the 782 infections overall.
Overall, success rates were higher in OPAT
patients (510⁄539 or 94.6%) than in IPAT patients
(354⁄410 or 86.3%) (p < 0.001, chi-square test)
(Table 3). OPAT patients with bacteremia and endo-
carditis had signiﬁcantly higher success rates, and
those with cSSSI had marginally higher success rates,
than IPAT patients with similar infections (Table 3).
Duration of daptomycin therapy
Patients who received only OPAT received a median
of 17 days (range: 3–144) and IPAT patients
received a median of 7 days (range: 1–153) of dap-
tomycin therapy. Patients who received IPAT plus
OPAT (i.e. 273 of the OPAT patients) received a
median of 5 days (range: 1–56) and 20 days (range:
3–358) of IPAT and OPAT daptomycin therapy
respectively.
Adverse events
A total of 216 adverse events were reported in 131
(13.8%) of the 949 patients. Fifty (9.3%) of 539
OPAT patients and 81 (19.8%) of 410 IPAT patients
experienced at least one adverse event (chi-square
test, p < 0.0001). Sixty-ﬁve patients experienced 89
adverse events evaluated as possibly related to dapto-
mycin therapy: 31 (5.8%) of 539 OPAT patients and
34 (8.3%) of 410 IPAT patients (chi-square test,
p = 0.12). A signiﬁcantly higher proportion of IPAT
patients (10 of 410 or 2.4%) vs. OPAT patients (one
of 539 or 0.2%) experienced possibly related diar-
rhoea (p = 0.001, Fisher’s exact test, two tailed).
Conversely, 14 of 539 (2.6%) OPAT patients and
four of 410 (1.0%) IPAT patients experienced crea-
tine phosphokinase elevations or myalgias (p = 0.08,
Fisher’s exact test, two tailed).
Daptomycin therapy was stopped because of one
or more adverse events in 19 (3.5%) OPAT patients
and 23 (5.6%) IPAT patients (p = 0.122, chi-square
test).
Table 1 Demographics and characteristics by location of daptomycin therapy
Characteristic OPAT patients IPAT patients Total p-value*
Female gender 236⁄538 (43.9) 226⁄409 (55.3) 462⁄947 (48.8) <0.001
Age > 50 305⁄539 (56.6) 259⁄410 (63.2) 564⁄949 (59.4) 0.041
Prior antibiotics 411⁄535 (76.8) 319⁄408 (78.2) 730⁄943 (77.4) 0.620
Consulted infectious diseases 483⁄539 (89.6) 378⁄410 (92.2) 861⁄949 (90.7) 0.174
Community location§ 275⁄536 (51.3) 154⁄410 (37.6) 429⁄946 (45.4) <0.001
Any healthcare location§ 251⁄536 (46.8) 254⁄410 (62.0) 505⁄946 (53.4) <0.001
No. of primary infections > 1– 61⁄539 (11.3) 67⁄410 (16.3) 128⁄949 (13.5) 0.025
No. of underlying diseases
Mean ± (SD) 1.89 (1.49) 2.72 (1.45) 2.25 (1.47) <0.001**
Median (minimum, maximum) 2 (0,5) 3 (0,5) 2 (0,5) <0.001
*Chi-square test unless otherwise indicated. No. with characteristic⁄no. of OPAT patients or IPAT patients (%). Denominators are not
all equal because of missing values. Potentially effective against gram-positive pathogens. §In the 48 h period before ﬁrst daptomycin
use. –For which daptomycin was prescribed; up to two primary infections were captured. **Student t-test. Median test.
OPAT, outpatient parenteral antibiotic therapy; IPAT, inpatient parenteral antibiotic therapy.
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Outpatient parenteral antibiotic therapy has become
established as a safe and effective alternative to IPAT
for selected patients in the USA. Several brief historical
reviews have highlighted the evolution of OPAT over
the past few decades, culminating in current estimates
of over 250,000 OPAT patients annually (1,2). A wide
variety of medical conditions have been treated with
OPAT and recommendations for patient selection and
management have been published (3,5,8–11).
A number of reviews have focused on the charac-
teristics of antimicrobials which would enable opti-
mal outpatient management. These characteristics
include appropriate pharmacokinetic and pharmaco-
dynamic proﬁles such as long half-life allowing for
infrequent dosing, chemical stability, short infusion
time, safety, and for certain infections, bactericidal
activity (4,12). In this respect, several characteristics
of daptomycin appear favourable to its use as OPAT:
a half-life of 8–9 h allowing for once-daily dosing,
concentration-dependent bactericidal activity, pro-
longed postantibiotic effect (> 6 h), relative stability
after reconstitution, short infusion time of 30 min,
and low frequency of injection site reactions (13–16).
In this analysis, OPAT patients had signiﬁcantly
higher success rates than IPAT patients. Undoubt-
edly, a major explanation for this ﬁnding was patient
selection; compared with IPAT patients, OPAT
patients were younger and were less seriously ill. In
addition, OPAT patients had fewer adverse events
than IPAT patients. In comparison to reports in the
literature, the percentage of OPAT patients in whom
daptomycin was stopped early because of an adverse
event, 3.5%, is similar, if not lower than the percent-
age of OPAT patients in whom courses of other anti-
biotics were stopped because of adverse events
(range: 2.9–9.8%) (5).
This analysis had a number of limitations includ-
ing its retrospective nature, moderate number of
Table 2 Infection type by location of daptomycin therapy
Type of infection
OPAT patients, no.
(% of OPAT patients)
IPAT patients, no.
(% of IPAT patients)
Total no. (% of
total infections) p-value*
Endocarditis 14 (2.6%) 15 (3.6%) 29 (3.1%) 0.349
Bacteremia 73 (13.5%) 143 (34.8%) 216 (22.8%) < 0.001
Osteomyelitis 98 (18.2%) 18 (4.4%) 116 (12.2%) < 0.001
Other 78 (14.5%) 75 (18.3%) 153 (16.1%) 0.113
cSSSI 177 (32.8%) 123 (30.0%) 300 (31.6%) 0.351
ucSSSI 99 (18.4%) 36 (8.8%) 135 (14.2%) < 0.001
Total 539 (56.8%) 410 (43.2%) 949 (100%) < 0.001
*Differences in proportion of infection type for OPAT patients vs. IPAT patients. Chi-square test unless otherwise indicated. Overall
table chi-square p < 0.001. Fisher’s exact test. no. (% of total infections). OPAT, outpatient parenteral antibiotic therapy; IPAT,
inpatient parenteral antibiotic therapy; cSSSI, complicated skin and skin structure infections; ucSSSI, uncomplicated skin and skin struc-
ture infections.
Table 3 Clinical outcome (success rates) by infection type and location of daptomycin therapy*
Infection type OPAT patients IPAT patients Total p-value*
Endocarditis 13⁄14 (92.9%) 6⁄15 (40.0%) 19⁄29 (65.5%) 0.005
Bacteremia 71⁄73 (97.3%) 116⁄143 (81.2%) 187⁄216 (86.6%) < 0.001
Osteomyelitis 89⁄98 (90.8%) 18⁄18 (100%) 107⁄116 (92.2%) 0.351
Other 71⁄78 (91.0%) 70⁄75 (93.3%) 141⁄153 (92.2%) 0.766
cSSSI 169⁄177 (95.5%) 110⁄123 (89.43%) 279⁄300 (93.0%) 0.064
ucSSSI 97⁄99 (98.0%) 34⁄36 (94.4%) 131⁄135 (97.0%) 0.289
All 510⁄539 (94.6%) 354⁄410 (86.3%) 864⁄949 (91.0%) < 0.001
*Differences in proportion of success for OPAT patients vs. IPAT patients. Fisher’s exact test (two tailed) unless otherwise indicated.
Overall table chi-square p < 0.0001. No. of successes⁄(no. of successes + no. of failures) (% success). Chi-square test. OPAT, out-
patient parenteral antibiotic therapy; IPAT, inpatient parenteral antibiotic therapy; cSSSI, complicated skin and skin structure infections;
ucSSSI, uncomplicated skin and skin structure infections.
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inpatient and outpatient centres participating in
CORE 2005, lack of information on comparator anti-
biotic treatments, and lack of randomisation. Signiﬁ-
cant outcome differences in favour of OPAT may
have been magniﬁed if unevaluable patients were
included in the analysis. Unevaluable patients were
disproportionately IPAT patients, had bacteremia,
and had more (serious) underlying diseases, factors
which might reasonably be associated with worse
outcomes. Finally, the ideal study comparing OPAT
and IPAT outcomes should be randomised (17).
That is, patients who would otherwise qualify for
OPAT therapy would be randomised into OPAT and
IPAT groups.
In conclusion, OPAT use was common (539⁄949
or 56.8%) among patients in CORE 2005. Clinical
outcomes among OPAT patients appeared at least as
good as or better than IPAT patients. Better out-
comes among OPAT patients were most likely
because of patient selection for OPAT. Additional
studies should focus on clinical characteristics of
patients who would be ideal candidates for daptomy-
cin OPAT.
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